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Abstract
Background: Off-label use of (orphan) medicinal products for (rare) diseases is quite common but not underpinned
by clinical studies to confirm efficacy and safety. No risk-analyses by regulatory agencies are carried out. The objective
of this study was to map off-label use of orphan medicinal products in Belgium in terms of attitude towards off-label
prescribing, factors influencing off-label prescribing, disclosure of information towards the patient, reporting of off-label
use, risks and consequences. Most of the EMA authorized orphan drugs are fully reimbursed in Belgium under
well-defined circumstances. Moreover, a “Special Solidarity Fund” takes care of some specific cases eventually
prescribed off-label.
Methods: Semi-structured interviews with seven physicians with expertise in the treatment with and six experts in the
reimbursement of orphan medicinal products in Belgium. This task was performed by five last-year pharmacy students
after having studied profoundly the medical literature around off-label prescribing. They had no previous contact with
the participants.
Results: Most participants do agree with the off-label use if the medicinal product is quite safe and well-tolerated,
if the on-label indication is rather general and when all other options have failed in some specific, evidence-based
indications, especially in children. Before starting off-label use, the patient/family needs to be fully and clearly
informed. The treatment is not reimbursed but sometimes sponsored by the company or by charity funds.
Reporting of the outcome is necessary to avoid losing valuable information. The prescriber is responsible and can
be held accountable.
Conclusions: While there is support from physicians and reimbursement experts, there is also concern in case of
off-label use, mainly for reasons of patient safety especially when medicinal products are prescribed off-label in the
absence of medical or scientific justification and driven by cost-containment motives.
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Background
Off-label use of a medicinal product entails the intentional
use of the medicinal product for any indication, popula-
tion, dosage, administration route or treatment duration
other than that approved by a country’s regulatory
authority [1]. For the most part, off-label use of medicinal
products is not underpinned by rigorous clinical and non-
clinical studies necessary to confirm quality, efficacy and
safety [2]. Off-label use of medicinal products is quite
common; 21 % of all prescription medicinal product use is
supposedly off-label. In some disease areas off-label use
can be as high as 83 % [1]. Only about 30 % of off-label
prescribing is supported by adequate scientific data [2].
According to Gupta et al. [2], off-label use is more com-
mon if standard treatments fail or are non-existent.
In the European Union, rare diseases are defined as
life-threatening or chronically debilitating diseases,
which occur at such a low prevalence (5 in 10,000 EU
citizens) that special initiatives are needed to address
them [3]. It is estimated that there are currently between
5000 and 7000 rare diseases. Orphan medicinal products
(OMPs) are intended to diagnose, prevent, or treat rare
diseases. With only 118 orphan medicinal products on
the European market at the beginning of 2016, only a
small part of the treatment need for rare diseases is
* Correspondence: steven.simoens@kuleuven.be
3KU Leuven Department of Pharmaceutical and Pharmacological Sciences,
Herestraat 49, PO box 521, 3000 Leuven, Belgium
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Dooms et al. Orphanet Journal of Rare Diseases  (2016) 11:144 
DOI 10.1186/s13023-016-0507-y
covered [4]. These OMPs are sometimes used off-label
for rare disease patients in case the ‘label’ imposes
certain restrictions; for example, some OMPs are used in
pediatric populations regardless of age restrictions [5].
Off-label use of OMPs in more common indications also
occurs; for example epoetin alfa was originally registered
in the US as an orphan medicinal product to treat
anemia in end-stage renal disease patients but its use
soon became more widespread [6]. Finally, rare disease
patients are also often being treated (off-label) using
other ‘non-orphan’ medicinal products. Rare disease
patients appear to be exposed to off-label use more often
than patients with more common diseases, partly due to
the limited number of patients [7]. Indeed, up to 90 % of
all medicinal product use for rare diseases is off-label
according to Liang et al. [1].
Yet, there are risks associated with off-label use;
clinical evidence demonstrating quality, safety and effi-
cacy is often lacking and no risk-analysis by regulatory
agencies is carried out [2, 8]. Although patients with a
life-threatening disease are likely to be more risk-
acceptant, EU legislation states that “patients suffering
from rare conditions should be entitled to the same
quality of treatment as other patients” [3]. As such, off-
label use of medicinal products for rare disease patients
has been compared to a double-edged sword; on the one
hand it might be a last resort for patients in unique life-
threatening situations, on the other hand, it also exposes
them to risks and experimentation [2].
Even though the extent of off-label use of OMPs
appears to be significant; Kesselheim et al. found that in
a sample of four top-selling orphan medicinal products,
three orphan medicinal products were used more com-
monly for non-orphan indications; the reasons behind
off-label prescribing of medicinal products for rare
disease patients are yet to be fully understood [6].
Therefore, the aim of this study was to map off-label use
of OMPs in Belgium in terms of attitude towards off-
label prescribing, factors influencing off-label prescrib-
ing, disclosure of information towards the patient,
reporting of off-label use, risks and consequences. This
study is based on the work of five pharmacy students in
the context of their Master theses at KU Leuven [9].
Mapping out these issues is a first step in achieving a
more systematic approach for appropriate off-label
prescribing.
While there is support for off-label use in specific cir-
cumstances, there is a growing trend towards promoting
the prescription of medicinal products off-label without
medical justification but for other motives such as cost-
containment and economic reasons [10, 11]. There is a
risk that these trends would compromise patient safety.
EU Member States are passing legislation, guidelines or
establishing practices promoting off-label use mainly to
reduce healthcare spending - for instance in Italy, France
and Denmark [12]. These practices create unnecessary
and avoidable risks for patients, often without their con-
sent. This view is supported by the European Court of
Justice, which has ruled that patient safety must always
prevail against any economic motives. The Court of
Justice confirmed this principle in its 2012 judgment in
the case Commission vs. Poland (C-185/10). The Court
concluded that Poland had been misusing a rule that
allows the use of medicinal products for named patients
and had been importing medicinal products that were
not authorized there, even though authorized equivalents
were available. The Court decided that the Polish law in-
fringed upon the marketing authorization requirements.
Methods
Semi-structured interviews were used as they enable the
interviewer to elaborate on specific aspects or insights of
the interviewee.
Participants
University Hospitals Leuven (Belgium) is a large tertiary
referral centre with broad experience in all rare disease
areas and orphan medicinal product use. A national
multidisciplinary consultation for rare diseases and
several national and international reference networks
operate in this hospital such as for haemophilia, cystic
fibrosis, spina bifida, pulmonary arterial hypertension,
amyotrophic lateral sclerosis, cystinosis, epidermolysis
bullosa, ichthyosis and neurofibromatosis. A total of 18
physicians treating rare diseases and/or using orphan
medicinal products from University Hospitals Leuven
and 9 experts involved with (orphan) medicinal product
policy and/or reimbursement procedures in Belgium
were contacted by e-mail to participate in this study. A re-
minder was sent after 1 week. Respondents were identified
through selective sampling by the authors. Respondents
who indicated to be willing to participate in the interviews
were contacted by e-mail for further arrangements con-
cerning time and place of the interview.
Interviews
A semi-structured interview guide was drafted based on
topics derived from a literature review which was under-
taken by the group of pharmacy students. Two experts
were given the opportunity to comment on the content
validity of this semi-structured interview guide, after
which it was adapted according to their comments. A
pilot interview took place on September 13th 2013.
Appropriate approval was obtained from University
Hospitals Leuven Medical Ethics Committee on July 12th
2013 (approval n° S55673).
All interviews were conducted between September
13th 2013 and November 7th 2013 by the group of five
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pharmacy students supervised by SS, MD and Eline
Picavet. All respondents signed an informed consent form
in duplicate. One copy of each form was kept by the
researchers. All respondents participated voluntarily and
were not remunerated. Anonymity of the participants and
confidentiality of the answers were guaranteed. The inter-
views were audio-recorded and transcribed verbatim.
Data analysis
The interviews were analysed using the software QSR
NVivo 10 according to the five stages of the framework
analysis: (1) familiarization (reading of the transcripts
and notes, listening to the digital recordings); (2) identi-
fying a framework; (3) indexing (application of the
framework to the data); (4) charting; and (5) mapping
and interpreting [13]. Selected quotes of the interviewees
were translated as accurately as possible.
Results
A total of seven physicians treating rare diseases and/
or using orphan medicinal products from University
Hospitals Leuven (Belgium) and six experts involved
with (orphan) medicinal product policy and/or reim-
bursement procedures in Belgium participated in the
study. All participants were coded according to their
background; i.e. physicians were assigned codes start-
ing with an A and policy experts were assigned codes
starting with a B.
Attitude towards off-label prescribing of OMPs
Most policy makers are not firmly in favor or against
off-label prescribing. Some only consider it appropriate
within the framework of a clinical study and if there is
no “on-label” alternative available.
“I’m against under the current conditions, data are
hardly being collected.” (BNY31102)
“I think it’s too simplistic to be “against” off-label use,
but I do think that it has to happen in the context of
study projects as much as possible.” (BES14101)
“Of course you have to check first whether there is no
approved medicinal product for that indication. But if
there isn’t, then off-label prescribing should have to be
possible.” (BNS11101)
“I think OMPs need to be prioritized here, because
they treat rare diseases. The clinical evidence will
always be limited, but if you have a proof of concept,
an idea of how a medicinal product works, then I
agree that it should be available for patients as
quickly as possible. It would even be unethical not to!.”
(BTY14102)
Factors influencing off-label prescribing
According to the interviewees several factors influence
the choice to prescribe an off-label treatment.
Safety and tolerability
The barrier to prescribe a medicinal product off-label is
lower if the medicinal product is considered safe and
well-tolerated.
“The most defining factor is the safety of the medicinal
product and whether or not it causes severe side
effects. You don’t want to make a patient even sicker
than he already is.” (AET13091A)
“Once you go off-label, I think safety is the most
important thing. Safety and tolerability. (…) Medicinal
products with a good safety profile have a better
chance of getting prescribed off-label.” (ANS02101L)
Effectiveness
All stakeholders agree that, although the evidence on the
effectiveness of a medicinal product may be limited,
treatment decisions should still be evidence-based.
Physicians keep up to date by following publications
within their area of expertise. New findings are also
discussed with national and international colleagues.
Peer-to-peer consulting is considered a crucial aspect,
even though the ultimate decision to start a new off-
label treatment is personal.
“You hardly ever have guarantees about the
effectiveness of a medicinal product in the off-label
indications. (…) But you need to have some sort of
scientific indication that it actually works. You can’t
just prescribe medicinal products and hope that
they will have an effect.” (AET13091A)
“I always consider: has this medicinal product been
tested in randomized studies? And I try to discuss it
with my assistants: why are we choosing this
medicinal product?” (AES14103A)
“There is a forum for questions about effectiveness and
cost-effectiveness of medicinal products used for
metabolic diseases. You can even add your own
questions. (…) That’s how you get feedback from
physicians worldwide. Sometimes is somewhat
subjective or not always based on objective criteria
from the literature, but along the way you learn to
distinguish between what is relevant and what is not.”
(AES14103A)
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Mechanism of action
Medicinal products with a more general and broad
mechanism of action, like some oncology medicinal
products, are more likely to be prescribed off-label com-
pared to other more targeted medicinal products such as
enzyme replacement therapies.
“These medicinal products [enzyme replacement
therapies] are used exclusively for very specific
indications, so I guess they are not used for any
other indications.” (ANS10101A)
“You can of course, based on the mechanism of action
of a medicinal product presume that it will probably
also be effective for a similar disease and just try it.
That is how it is often done.” (ANS10101A)
Place in clinical practice
Off-label prescribing is seldom applied as first-line therapy.
It is considered when all other options have failed.
“At the end of what is feasible, or what is reimbursed,
or what is “standard”, then you resort to off-label
prescribing.” (ANS02101L)
Disease indication
Off-label prescribing is more frequent in some specific
indications
“There are 1001 medicinal products to treat heart
arrhythmia. If product A fails, then try product B. And
all these are registered and reimbursed. There is no
such thing in hemato oncology! Additionally,
medicinal products in hemato oncology are mostly
expensive, monoclonal antibodies and small molecules.
Off-label use is a lot more frequent in hemato oncology.”
(ANS02101L)
Patient population
A final determining factor is the patient population.
Children are subjected to off-label use more often than
adults because not all medicinal products are registered
for paediatric use.
“Yes, in neonatology intensive care, I think it will be
up to 80 or 90 % off-label. Almost every leaflet states
that the medicinal product can’t be used in children.”
(AET07111C&N)
Disclosure of information towards the patient or family
Before starting an off-label treatment, the patient needs to
be informed about the working mechanism and risks asso-
ciated with the treatment. According to the interviewees
it’s important that patients are aware that the indication is
not officially registered and that the clinical evidence is
limited.
“We basically don’t have a choice, if it isn’t a
registered indication. It’s something between an
experiment and standard common practice, so we ask
for permission.” (AET1309A)
“The decision to prescribe an off-label medicinal
product is made in consultation with the patient.”
(BNS02101)
“Yes, we need informed consent. A patient HAS to say:
‘I share responsibility’. Provided of course that the
patient has been informed correctly.” (BTY14102)
The information provided to the patient regarding
the off-label treatment must be clear and comprehen-
sible. All too often, specialist jargon is used, causing
patients to given their consent based on unclear
information. In general, patients and their family do
not oppose off-label use.
“The specific jargon is sometimes incomprehensible to
the patient, so it needs to be explained very clearly.
And I’m not saying that the information should be
trivialized or popularized, but still… (…) Patients are
sometimes desperately looking for a last remedy, so it’s
not uncommon that they agree too easily or too
quickly.” (BTY14102)
“Also, the physician needs to have the information
himself! I think there is a role there for the industry.
They know their medicinal product, they can say ‘these
are the limitations’.” (BTY14102)
“If there aren’t any alternatives, and the patient is
very sick, he is likely to be happy with any alternative.
Most patients don’t oppose.” (AET13091A)
“We mustn’t forget that, these days, patients are well
informed! They scan the internet, find a product and
suggest it to ME. And if it is not available, we try to
get it.” (ANS02101L)
Physicians inform patients that there is a chance that
the treatment is stopped because of lack of effectiveness
or because of financial reasons. To avoid disappointments,
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a timeframe in which an effect should be noticeable is
agreed upon in advance.
“At a certain point, we stopped using the medicinal
product and the family agreed. They also had the
impression that that was for the best. We had
discussed this on beforehand.” (AES14103A)
“If it doesn’t have the desired effect after a certain
time, then you stop the treatment. But we have this in
mind in the beginning. For example, after four courses
of treatment, if it doesn’t have an effect, we stop
trying.” (ANS02101L)
Financing and budget for reimbursement
Off-label use is not officially reimbursed.
“Reimbursement is limited to the indications mentioned
in the SpC. Sometimes it is even more limited, but never
more broad. So off-label use is not reimbursed. But the
physician can prescribe it for another reimbursed
indication of course.” (BNS11101)
“I think we should be very careful with reimbursement
of off-label use. If too much is ‘allowed’, then companies
no longer will be motivated to apply for new indica-
tions and to perform their own studies. But sometimes,
there is no other choice, just to help patients!”
(BES14101)
In practice, off-label use is avoided in case there
would be an associated financial burden for patients
or family. In some cases the company offers the
product for free. If not, financial support can be
offered by special governmental funds (i.e. the Excep-
tional Solidarity Fund in Belgium) or (charity) funds
from hospitals.
“The patient feels no financial burden, because we
make sure of it! We want to avoid that people do
crazy things, like selling their house, to pay for a
treatment that won’t necessarily benefit them.”
(ANS0201L)
“We mostly try to get the product from the
company. Other options are national or internal
solidarity funds. But these are exceptions! The
odds of getting a positive response there are
very small.” (ANS02101L)
“We [at the hospital] have an internal solidarity fund,
but there is hardly any money available. I think if we
were to treat one patient with an enzyme replacement
therapy, well that would drain the fund completely for
the rest of the year.” (AET13091A)
Finally, reimbursement can also be obtained by willfully
falsifying medical certificates.
“Off-label use is not reimbursed, unless we claim that
the product will be used to treat a reimbursed
indication. For example if one subgroup is reimbursed,
but the other is not, then you can prescribe everything
for that first subgroup. But if you get caught… you can
pretend you made a mistake once, but not ten times!
I’m not going to deny that we sometimes bend the
rules like that.” (ANS02101L)
“Sometimes companies send delegates to physicians to
explain how they can by-pass the law, which boxes to
check on the application form. Of course it’s cheaper
for them! And in the end, they are not responsible;
when problems arise, well they say ‘it’s off-label use’.”
(BES14101)
The total share of the entire pharmaceutical budget
allocated to off-label orphan medicinal product use is
not easily determined. Interviewees disagree on whether
or not this share is high or low.
“It can be high, I would guess up to 50 % of the total
orphan medicinal product budget. But there is no way
to determine it, it’s a speculation.” (BES14101)
“You could map it, but that would be very difficult! I
guess because orphan medicinal products are only
used for a limited number of patients the off-label
budget will be limited.” (BTY14102)
Reporting of off-label use
In practice, off-label use is seldom reported in the
literature. Publishing individual case studies is not
considered worth the effort. Nevertheless, experts
agree that reporting of off-label use is necessary to
avoid losing valuable information. A European data-
base is considered an option.
“Well I have to admit that the pressure to publish
positive results is bigger than to publish bad results.
Bad results do not get published, period.”
(ANS02101L)
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“Case reports are just cast reports with little scientific
value. (…) I’m more in favor of organizing clinical
studies or registers or systems in which results are
somewhat grouped.” (BES14101)
“Yes, I think we have to report it for these rare
conditions simply because the medicinal products are
so expensive. (…) It would even be best to organize it
on a European level. For example, everybody using an
orphan medicinal product off-label, registering that
use in a European database.” (AES14103A)
There is no agreement on whether or not such database
should be anonymous. Anonymity protects the physician,
so that the barrier for reporting negative experiences is
lowered.
“Anonymizing, that’s an option. It can possibly help to
also publish negative experiences.” (BNS11101)
“That the physician is anonymous? Well yes of course!
(…) But, if someone else wants more information, how
would that work? Why would physicians want to
remain anonymous? I can imagine that all of us are
trying to achieve improvements in medical science,
and that you stand by your own decisions and take
responsibility for them.” (AET13091A)
“Of course it’s useful! You want to spare others the
mistakes that you made. Well it doesn’t necessarily
even have to be a failure, but just a ‘lack of effect’, I
think it’s also useful to report that. So others won’t
try the same thing.” (AET13091A)
“Absolutely, those negative experiences give you a much
bigger picture! Nowadays everybody has a feeling of
‘wow this works well off-label’, but in fact, you don’t
know about all the failed attempts.” (ANS02101L)
A recurring concern is the amount of paperwork
involved in reporting off-label use. A simple form of
reporting should therefore be considered. Some high-
light the need for a regulatory framework.
“We simply don’t have the time to do all that
publishing and reporting.” (AEY11101L)
“This database, it won’t be easy to implement. At the
moment there is no legal framework, and I think that
is needed first.” (BNS11101)
Some physicians already use disease specific registers
to keep track of off-label use.
“For some conditions, or groups of conditions, there are
international registers. I try to participate in those.
It gives me a lot of information! If everyone has five
patients, that’s not informative, but all together, well




The most important risk, according to the interviewees,
is failure of the off-label treatment, either due to failure
to achieve the desired effect or due to the occurrence of
serious adverse events.
“Based on the literature we thought, we have to do
something and this looks promising. In practice, it
didn’t play out well.” (AES14103A)
“It isn’t always 100 % clear what the effects and the
adverse events will be.” (AET13091A)
Accountability
The prescriber is responsible for off-label prescribing
and can be held accountable. Most physicians do not con-
sider this a big risk. None of the interviewed physicians
had negative experiences.
“A physician has therapeutic freedom and can
prescribe off-label. But it is a risk! Companies and
pharmacists will not cover the physician’s back if
anything goes wrong.” (BNS11101)
“A risk? Not really. We prescribe so many strange
medicinal products.” (AEY11101L)
“It is not a risk, it’s based on the literature and you
discuss it with patient beforehand. Everybody knows
what the risks are. In my opinion, the only risk is the
reimbursement of the product.” (ANS02101L)
Funding problems
Another risk is the lack of a posteriori financing. In most
cases, a treatment is started before reimbursement or
funding through alternative channels has been approved.
Treatment can be stopped abruptly if these fail.
Incentives for future development
Pharmaceutical companies may wish to extend the
indication of an orphan medicinal product. However, the
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risk of downward pressure on the price and the efforts
needed to collect data are important hurdles.
“But I think you have to be careful to extend an
indication, because that’s a practice that companies
strive for. They put a product on the market in a
small niche market, but their actual target group is
much wider to be able to make profits.”
(AES14103A)
“Why don’t they [pharmaceutical companies] file for
additional indications? Because when that happens,
they have to lower the price! It’s an odd situation of
course.” (BNS02101)
“Companies are not interested. Why would they be?
Their product is the only one on the market… If
they change the application, then it has to be based
on clinical studies. And the evidence is already
there, because physicians are collecting it. Is it
worthwhile to trouble children again?? There is a
lot more behind it than the motivation of the
company.“ (AET07111C&N)
“It is not easy to collect data in these very small
patient populations! This implies that the number
of phase II and III clinical studies is limited, and
that the duration of these studies may be limited.”
(BNS02101)
“From a societal point of view it is sometimes
frustrating that we can’t force a company to
extend an indication.” (BES14101)
Future perspectives
According to some policy makers, off-label prescribing
should be limited to expert centers.
“I don’t think everybody should be allowed to prescribe
everything. We trust expert centers, we determine their
expertise, they fulfill all our conditions. Then they also
should be able to prescribe off-label in a responsible
way.” (BNS02101)
Discussion
This study has mapped off-label use of OMPs in
terms of attitude towards off-label prescribing, factors
influencing off-label prescribing, disclosure of infor-
mation towards the patient, reporting of off-label use,
risks and consequences in Belgium. Our results show
that off-label prescribing of OMPs is a common practice,
especially when alternative treatments are lacking. A legal
framework should put all parties involved at ease.
It is our opinion that off-label prescription should only
occur after individual assessment by the treating
physician of the needs of the individual patient. Physi-
cians need to be given the freedom to uphold their
pledge towards their patients to act ethically and put
the patient’s interest first. They should be supported
by the public bodies and authorities responsible for
the approval and usage of medicines whose role is to
protect public health. Patients should be informed
about the off-label use and the consequences. Lately,
a new trend to tackle this issue appeared. Novartis
brought the same active ingredient (everolimus) in
the same dose and the same pharmaceutical form on
the market but under two different names: Afinitor®
for use in oncology and Votubia® for the treatment of
tuberous sclerosis. Boehringer Ingelheim did the same
with nintedanib: Ofev® with interstitial pulmonary
fibrosis on the label and Vargatef® with an oncology
label.
Pharmaceutical companies are not allowed to mention
potential off-label uses for their already marketed
products. However, they can ask for a second or fur-
ther medical use claim or an orphan designation
when the indication is rare. Other companies repur-
pose off-patent active ingredients in another medica-
tion for an already known off-label use: ibuprofen
injection as Pedea® and 3,4-diaminopyridine capsules
as Firdapse®. When a medicinal product is taken from
the market by the pharmaceutical company as the on-
label indications become outdated for example, off-label
users lose their treatment: Calcort® (deflazacort) for
Duchenne muscular dystrophy and Mexitil® (mexilitine)
for rare forms of myotonias. Payers sometimes reimburse
off-label use but mostly they wish the companies to prove
safety and efficacy before they consider reimbursement:
thalidomide is reimbursed in several rare dermatologic
indications in Belgium such as prurigo nodularis,
Osler-Weber-Rendu and Behçet disease.
In the academic literature, there is a tendency to
report only positive experiences with off-label prod-
ucts rather than recording adverse events [14–18].
Literature can therefore be unbalanced and an effort
should be made to publish articles and reports of
adverse events linked to the off-label use of a product. It
is crucial for patients and physicians to report adverse
events and outcomes as accurately as possible with a view
to install guidelines for the potential treatment of these
conditions with OMPs. Furthermore, the use of patient
registries should be encouraged. The EudraVigilance
platform, the European data processing network and
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management system for reporting and evaluating
suspected adverse reactions could be used to gather better
data on adverse effects by patients as well as medical
professionals. Recently, pharmaceutical companies need
to register pharmacovigilance even for off-label use of
their pharmaceutical products.
This qualitative study mapped out off-label use of
OMPs through in-depth interviews with both policy
makers as well as physicians. However, this study was
subject to some limitations. The outcome of an inter-
view is dependent on the experiences and expertise of
both the interviewer and the interviewee on the topic.
Moreover, the use of a pre-defined, semi-structured
interview guide can limit the course of the interview and
the issues discussed. Future research should not only
include the experiences of physicians in a university
hospital (which acts as a referral centre for patients with
rare diseases), but also be extended to physicians in
general hospitals.
Conclusions
This study showed that off-label use can be useful espe-
cially in the treatment of patients with rare diseases.
However, we need some guidelines [12] to protect pa-
tients and practitioners, and to avoid cost-containment
practices compromising patient safety. Therefore, we
propose that off-label use of medicinal products should
only occur if the following criteria are met:
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